Market Research Report
Cervical Cancer- Market Insight, Epidemiology and Market Forecast -2030
|Published by||DelveInsight Business Research LLP||Product code||963733|
|Published||Content info||174 Pages
Delivery time: 1-2 business days
|Cervical Cancer- Market Insight, Epidemiology and Market Forecast -2030|
|Published: October 14, 2020||Content info: 174 Pages||
DelveInsight's 'Cervical Cancer -Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Cervical Cancer in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Cervical Cancer market report provides analysis regarding current treatment practices, emerging drugs like Cemiplimab, Durvalumab, LN-145, Z-100, Tisotumab vedotin, promising therapies, market share of the individual therapies, and historical, current and forecasted Cervical Cancer market size from 2017 to 2030, segmented by seven major markets.
The report also covers current Cervical Cancer treatment practice/algorithm, guidelines, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.
Study Period: 2017-2030
Cervical cancer is one of the most common gynecological tumors that occur in the cells of the cervix. The most significant cause of cervical cancer is persistent papillomavirus infection. Gynecological cancers are among the most common cancers in women. Cervical cancer is the most common type of gynecological cancer. Indeed, it is one of the major public health problems in the world and one of the top causes for disability-adjusted life-years (DALYs). Yet, cervical cancer is one of the most preventable cancers. HPV is the most common sexually transmitted infection worldwide and is the cause of almost all cases of cervical cancer. Because precancerous lesions can be found by the Papanicolaou (Pap) test and treated and cured, cervical cancer is often detected before it becomes advanced.
The standard management of patients with early-stage (FIGO stage IA-IB1) cervical cancer is a radical hysterectomy and lymph node dissection and/or radiation with or without chemotherapy. The standard management of individuals with locally advanced cervical cancer includes external beam radiotherapy with concurrent cisplatin-based chemotherapy with brachytherapy.
This chapter covers the details of conventional and current medical therapies available for the treatment of Cervical Cancer. It also provides Cervical Cancer treatment guidelines across the United States, Europe, and Japan.
DelveInsight's Cervical Cancer market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Cervical Cancer treatment algorithms and treatment guidelines in the US, Europe, and Japan.
The Cervical Cancer epidemiology chapters provide insights about historical and current Cervical Cancer patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Cervical Cancer epidemiology is segmented by the Incident cases of Cervical Cancer, Stage-specific Incidence of Cervical Cancer, Histopathologic Types of Cervical Cancer, Age-specific cases of Cervical Cancer. Besides, the report includes a thorough analysis of all segments.
According to DelveInsight's , the total prevalent population of Cervical Cancer in seven major markets was 43,514 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).
Among all the seven major markets, total prevalent cases for Cervical Cancer were highest in the United States, followed by Japan and Germany. Spain accounted for the least number of prevalent cases among the 7MM.
This segment encloses the detailed analysis of the drugs in the Cervical Cancer pipeline. It also helps understand the cervical cancer clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.
Therapies administered for treatment of metastatic or recurrent cases comprises systemic therapies, which include paclitaxel plus cisplatin-based doublets or triplet combination therapies. Over the past three decades, these have remained the mainstay or standard of care (SOC) without vastly impacting the median overall survival (OS) of patients with stage IVB or recurrent disease despite multiple studies with single-agent or combination chemotherapy. FDA approved drugs include Avastin, Keytruda and Hycamtin.
The market size of Cervical Cancer is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounted for the largest Cervical Cancer market size. Among EU5 countries, Germany, in 2017, had the largest market size with USD 25.46 million, while Spain had the smallest market size of USD 0.34 million.
This section focuses on the rate of uptake of the potential drugs in the Cervical Cancer market or expected to get launched in the market during the study period 2017-2030. The analysis covers Cervical Cancer market uptake by drugs; patient uptake by therapies; and sale of each drug.
It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Cemiplimab (Regeneron), Durvalumab (AstraZeneca), LN-145 (Iovance), Z-100 (Zeria Pharmaceutical), Tisotumab vedotin (Seattle Genetics/Genmab) are the major players that are going to alter the market dynamics in the coming years, during the forecasted period 2020-2030.
Cervical Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics.
Pipeline Development Activities:
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning Cervical Cancer .
To keep up with current market trends, we take KOLs and SME's opinion working in Cervical Cancer domain through primary research to fill the data gaps and validate our secondary research. It will support the clients in assessing potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We have performed the competitive and market Intelligence analysis of the Cervical Cancer Market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. Besides, the inclusion of the analysis entirely depends upon the data availability.
Cervical Cancer Report Insights:
Cervical Cancer Report Key Strengths:
Cervical Cancer Report Assessment:
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
Reasons to buy:
Which geography accounted for the largest Cervical Cancer market size?
The United States accounted for the largest Cervical Cancer market size.
What is forecasted Cervical Cancer size in 2030?
DelveInsight estimates an increase in Cervical Cancer Market Size during the study period, 2017-2030
What are the present Cervical Cancer market drivers?
Advancements in treatment, improvement in preventive measures, early detection of disease, therapies in development for recurrent and relapsed cases,
What are the Cervical Cancer market barriers?
Insufficient data on disease biomarkers, barriers in screening, access to palliative care, costs associated with treatment
How many companies are developing drugs for Cervical Cancer?
Currently, six key pharma players are developing the drug for Cervical Cancer
Which are the leading companies in Cervical Cancer market?
Key Players - Regeneron, AstraZeneca, LN-145, Zeria Pharmaceutical, Seattle Genetics/Genmab, Advaxis
How is epidemiology segmented for Cervical Cancer?
Incident cases of Cervical Cancer, Stage-specific Incidence of Cervical Cancer, Histopathologic Types of Cervical Cancer, Age-specific cases of Cervical Cancer
Forty-year timeline of public health research and policy on HPV and cervical cancer